FRANK GOLDEN: Open Payments
NPI 1033704051 · LEHIGHTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,847 in 104 payments from 14 companies in 2025. Trend: 2023 $2,090 · 2024 $1,392 · 2025 $1,847
Food & beverage: $1,847
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $353 |
| ABBVIE INC. | 21 | $314 |
| Otsuka America Pharmaceutical, Inc. | 13 | $299 |
| Alkermes, Inc. | 11 | $215 |
| Vanda Pharmaceuticals Inc. | 10 | $169 |
| E.R. Squibb & Sons, L.L.C. | 13 | $162 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $74 |
| Janssen Pharmaceuticals, Inc | 3 | $59 |
| Lundbeck LLC | 3 | $45 |
| Braeburn Inc. | 2 | $42 |
Products named: INGREZZA, VRAYLAR, REXULTI, ARISTADA, COBENFY, FANAPT, CAPLYTA, INVEGA SUSTENNA.
Industry payments across PA — which companies pay providers there.
